Michael Benz, MD
Interventional Cardiology · Jersey City, NJNPI 1548352438
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 33.7% of the total.
Across 434 payments — averaging $91.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$13K
- Abbott$8K
- Edwards Lifesciences$6K
- Medtronic$3K
- ZOLL Circulation Inc$2K
- GSK$1K
- plus $6K from 21 others
What the payments were for
- Speaking & faculty fees$12,75032%
- Travel & lodging$3,1808%
- Food & beverage$23,77560%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 55 | $13,390 |
| Abbott | 98 | $7,871 |
| Edwards Lifesciences | 54 | $6,241 |
| Medtronic(2 entities) | 98 | $3,268 |
| ZOLL Circulation Inc | 8 | $1,767 |
| GSK | 10 | $1,012 |
| Abiomed | 12 | $998 |
| Boston Scientific | 28 | $948 |
| AstraZeneca | 19 | $731 |
| E.r. Squibb & Sons, L.L.C. | 10 | $550 |
| Boehringer Ingelheim | 4 | $474 |
| Cardiovascular Systems Inc. | 4 | $376 |
| Johnson & Johnson | 3 | $371 |
| Inari Medical, Inc. | 4 | $271 |
| Heartflow, Inc. | 2 | $211 |
| Shockwave Medical, Inc | 2 | $195 |
| W. L. Gore & Associates, Inc. | 5 | $184 |
| Impulse Dynamics (USA) Inc. | 1 | $135 |
| Philips North America LLC | 1 | $123 |
| Cardiva Medical, Inc. | 4 | $122 |
| Biotronik Inc. | 1 | $118 |
| Pfizer | 3 | $110 |
| Biosense Webster, Inc. | 1 | $99 |
| AbbVie | 4 | $78 |
| Stryker | 1 | $24 |
| Penumbra, Inc. | 1 | $22 |
| Cordis US CORP. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$11,851
- TherOx DS2 Console$1,512
- Catheter$1,512
- Downstream Cartridge$1,512
- TRICLIP$1,363
- SAPIEN 3 Ultra RESILIA$1,257
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$1,217
- Confirm Rx$1,194
- TRELEGY ELLIPTA$839
- Edwards SAPIEN 3 Transcatheter Heart Valve$758
- Impella$711
- JARDIANCE$474
- AVEIR$444
- CoreValve Evolut$431
- Quadra Assura CRT Defibrillator$372
- ELIQUIS$366
- COREVALVE EVOLUT R$296
- XARELTO$275
- OPTIMIZER$271
- Watchman$267
How this compares
$39,705 in reported general payments places this provider in the 80th percentile of 166 interventional cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 180 | $173,113 |
| EntrestoSacubitril/Valsartan | 65 | $58,984 |
| XareltoRivaroxaban | 29 | $32,927 |
| BrilintaTicagrelor | 16 | $18,151 |
| Ranolazine ErRanolazine | 46 | $4,530 |
| Rosuvastatin Calcium | 148 | $2,974 |
| Atorvastatin Calcium | 156 | $2,168 |
| ClopidogrelClopidogrel Bisulfate | 140 | $1,969 |
| Metoprolol Succinate | 122 | $1,899 |
| Losartan Potassium | 154 | $1,766 |
| Diltiazem Hcl | 36 | $1,024 |
| Hydralazine Hcl | 79 | $969 |
| Amlodipine Besylate | 166 | $842 |
| Carvedilol | 64 | $708 |
| Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid | 13 | $665 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $110 | $173,113180 claims |
| Johnson & JohnsonXarelto | $371 | $32,92729 claims |
| AstraZenecaBrilinta | $731 | $18,15116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 166 interventional cardiology providers in New Jersey.
Other interventional cardiology in Jersey City
- Ankitkumar PatelGlen Ridge$408K
- Ziad AbbudOcean$360K
- Ramin HastingsHasbrouck Heights$295K
- Michael LimHackensack$215K
- Darshan GodkarCedar Knolls$194K
- Ryan KapleHackensack$178K
- Matthew SayboltEatontown$175K
- Daniel KissEatontown$172K
- Kintur SanghviBordentown$139K
- Dimitrios KarmpaliotisMorristown$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.